KPV
KPV is a naturally occurring three-amino-acid peptide derived from alpha-MSH, a hormone involved in inflammation control. Research focuses on its strong anti-inflammatory properties, particularly in inflammatory bowel disease and skin conditions.
A leading innovator in research chemicals.
|Exclusive OfferUse our affiliate link and code PEPTIDEWIKI at checkout to unlock your 10% discount, every time you use the code.
Shop NowFor research purposes only. PeptideWiki may earn a commission at no extra cost to you.
KPV
For research purposes only. PeptideWiki may earn a commission at no extra cost to you.
Overview of KPV
Exerts anti-inflammatory effects by entering cells and inhibiting NF-kB activation, reducing pro-inflammatory cytokine production without melanocortin receptor binding.
Enters inflammatory cells through PepT1 transporter and directly inhibits NF-kB nuclear translocation, suppressing inflammatory gene transcription.
Reduces production of TNF-alpha, IL-6, and IL-1beta in activated macrophages (proposed), attenuating inflammatory cascades.
Anti-inflammatory activity is independent of melanocortin receptors, distinguishing it from full-length alpha-MSH.
Reduces colonic inflammation in IBD models, decreasing inflammatory cell infiltration and mucosal damage.
May preserve intestinal barrier integrity (proposed), reducing permeability associated with inflammatory bowel conditions.
Reduces inflammatory responses in skin cells (proposed), with potential applications in dermatitis and wound healing.
Small size (tripeptide) allows for potential topical and oral delivery, improving bioavailability options
Read Full KPV Dosage Guide
Research-backed dosing protocols, timing, and administration details
Browse more in this category
Immune & Inflammation
Are Oral Peptides Here? Inside the Breakthrough and What's Next
Oral semaglutide just proved cardiovascular benefit, Eli Lilly cleared Phase 3, and a microneedle pill raised a billion dollars. Where the oral peptide era actually stands, and what it means for research peptides.
RFK Jr. Says 14 Peptides Are Coming Back: Ban Reversal
HHS Secretary RFK Jr. told Joe Rogan that ~14 peptides banned by the FDA in 2023 will return to Category 1, restoring legal compounding access.